Table 5.
Cox regression analysis of the factors for PFS with sorafenib treatment after lenvatinib in patients with advanced HCC
| Variables | Univariate analysis | p value | Multivariate analysis | p value | ||||
|---|---|---|---|---|---|---|---|---|
| hazard ratio | 95% CI | hazard ratio | 95% CI | |||||
| Sex, male | 1.070 | 0.360–3.177 | 0.903 | |||||
| Age, >73 yr old | 0.975 | 0.452–2.103 | 0.949 | |||||
| Child-Pugh class B | 2.755 | 1.248–6.078 | 0.012 | 2.755 | 1.248–6.078 | 0.012 | ||
| HBV positive | 0.992 | 0.233–4.225 | 0.992 | |||||
| HCV positive | 1.333 | 0.610–2.911 | 0.471 | |||||
| Intrahepatic tumor volume, >50% | 2.380 | 0.549–10.313 | 0.247 | |||||
| BCLC C | 1.145 | 0.509–2.577 | 0.743 | |||||
| Baseline AFP, >400 ng/mL | 2.208 | 0.974–5.010 | 0.058 | |||||
| Responder to lenvatinib | 0.896 | 0.414–1.941 | 0.781 | |||||
| Discontinued lenvatinib after radiological progression | 1.819 | 0.758–4.367 | 0.181 | |||||
| Treatment duration of lenvatinib, >4.9 mo | 1.292 | 0.558–2.988 | 0.550 | |||||
HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; CI, confidence interval; PFS, progression-free survival.